Daxor Awarded $550K U.S. Defense Health Agency Contract For Added Capabilities To Its Point-Of-Care Blood Volume Analyzer

7/24/24 8:21:38 AM ET

Medical/Dental Instruments

Health Care

Get the next $DXR alert in real time by email

The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA)

Oak Ridge, TN, July 24, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that Daxor has received a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This additional funding will support adding hematocrit measurement to a future generation blood volume analyzer. The upgrade eliminates the need for hematocrit testing from third-party devices to perform the BVA test.

Get the next $DXR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DXR

Date	Price Target	Rating	Analyst

More analyst ratings

$DXR
Press Releases

Fastest customizable press release news feed in the world

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24
Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference being held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, October 17-19, 2024. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting cardiovascular thought-leaders from across the country to transform cardiovascular care together with leading industry innovators. "We look forward to engaging with i
10/9/24 8:00:00 AM ET
$DXR
Medical/Dental Instruments
Health Care
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Oak Ridge, TN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Maxim Director of Research and Senior Healthcare Analyst Anthony Vendetti. The summit is being held from October 15 – 17, 2024. Event:Fireside Chat at 2024 Maxim Healthcare Virtual SummitDate:Tuesday, October 15, 2024Time:10:00 AM ETWebcast:https://m-vest.com/events/healthcare-10152024 Mr. Feldschuh will be available for one-on-one meetings with registered investors of the summit. Interested investors may also
10/8/24 8:00:00 AM ET
$DXR
Medical/Dental Instruments
Health Care
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device
Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market Oak Ridge, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces a strategic update to its regulatory approach for its novel diagnostic blood volume analyzer platform. Following productive discussions with the U.S. Food and Drug Administration (FDA), the company has decided to withdraw its current dual 510(k)/CLIA-waiver application and resubmit a focused 510(k) application. This decision comes after considerable progress in addressing key regulatory considerations and aims to expedite the approval process, potentially bringing t
9/27/24 5:00:00 PM ET
$DXR
Medical/Dental Instruments
Health Care

$DXR
Financials

Live finance-specific insights

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base. Daxor projects the acquisitions to be cash flow positive and accretive to earnings imm
3/25/24 8:00:00 AM ET
$DXR
Medical/Dental Instruments
Health Care
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Concentrate all your thoughts upon the work in hand. The sun's rays do not burn until brought to a focus." - Alexander Graham Bell We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume meas
3/18/24 2:18:00 PM ET
$DXR
Medical/Dental Instruments
Health Care
Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022
Conference Call to be held today at 9:00 AM EST Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December 31, 2022. Management reported a NAV of $6.75 per share for fiscal 2022 versus $5.24 for the comparable period in 2021, a $1.51 increase or 36.95%, as well as a 20.5% increase in unaudited revenues and sales for its operating division, which produces and distributes its blood volume analysis (BVA) diagnostic systems and single use test kits which rose by 59.5%. "We a
3/2/23 7:00:00 AM ET
$DXR
Medical/Dental Instruments
Health Care

Daxor Awarded $550K U.S. Defense Health Agency Contract For Added Capabilities To Its Point-Of-Care Blood Volume Analyzer

Chat with this insight

Recent Analyst Ratings for
$DXR

$DXR
Press Releases

Fastest customizable press release news feed in the world

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

$DXR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Desrosiers Caleb

SEC Form 4 filed by Director Goudie Joy S.

SEC Form 4 filed by Director Feuer Edward

$DXR
SEC Filings

SEC Form N-PX filed by Daxor Corporation

SEC Form N-CSRS filed by Daxor Corporation

SEC Form 40-17G filed by Daxor Corporation

$DXR
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Michel Robert J bought $6,525 worth of Daxor Common Stock (750 units at $8.70), increasing direct ownership by 7% to 11,300 units (SEC Form 4)

Feuer Edward bought $7,210 worth of Daxor Common Stock (1,000 units at $7.21) (SEC Form 4)

Michel Robert J bought $930 worth of Daxor Common Stock (120 units at $7.75), increasing direct ownership by 1% to 10,550 units (SEC Form 4)

$DXR
Financials

Live finance-specific insights

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022

$DXR
Market Insights

Live Market Insights

$DXR
Leadership Updates

Live Leadership Updates

$DXR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.